ArticleJournal of molecular medicine (Berlin, Germany)2025
ApoA5-CIDEC axis regulates hepatic lipid metabolism, inflammation, and fibrosis in MASLD.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Apolipoprotein A5 (ApoA5) and Cell Death-Inducing DNA Fragmentation Factor-like Effector C (CIDEC) are involved in hepatic lipid metabolism and implicated in metabolic dysfunction-associated steatotic liver disease (MASLD). This study explores the role of the ApoA5-CIDEC interaction in regulating hepatic lipid metabolism, inflammation and fibrosis in MASLD. C57BL/6 J mice were used to evaluate hepatic steatosis, liver function, and fibrosis under different ApoA5 expression conditions. Co-immunoprecipitation and immunofluorescence confirmed ApoA5-CIDEC interaction on lipid droplets (LDs). HepG2 cells were used to assess the effects of ApoA5 and CIDEC on triglycerides (TG), free fatty acids (FFAs), fatty acid beta-oxidation (FAO), and de novo lipogenesis (DNL). Key lipid metabolism and inflammatory markers, including fatty acid-binding protein 4 (FABP4), were analyzed. ApoA5-overexpression in mice improved hepatic steatosis, function, and fibrosis, reducing TG, FFAs, DNL, ApoB secretion, and pro-inflammatory cytokine secretion (IL-6, IL-1β, TNF-α), while enhancing FAO in HepG2 cells. ApoA5-knockdown led to opposite effects. ApoA5 and CIDEC co-localized with LDs, interacting with FABP4 to jointly regulate lipid metabolism and inflammation. The effects of ApoA5 were mediated through reduced CIDEC expression. ApoA5 regulates hepatic lipid metabolism, inflammation, and fibrosis through its interaction with CIDEC. Targeting the ApoA5-CIDEC axis may provide a novel therapeutic approach for treating MASLD. KEY MESSAGES: ApoA5 reduces hepatic fibrosis and inflammatory cytokine secretion. ApoA5 interacts and co-localizes with CIDEC on lipid droplets. ApoA5-CIDEC interaction regulates lipid metabolism and inflammatory cytokine secretion in hepatocytes. ApoA5-CIDEC axis regulates FABP4 expression. Targeting the ApoA5-CIDEC axis offers therapeutic potential for MASLD.
Indexed as
Identifiers
41392209What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.